Clinical Trial Update: Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial on augmenting cerebral blood flow to treat established multiple sclerosis has been terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Multiple Sclerosis | Phase 2 | Status: TERMINATED | Results posted: 2023-03-01